Last 7 days
-0.1%
Last 30 days
-4.4%
Last 90 days
1.9%
Trailing 12 Months
-28.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MDT | 105.3B | 30.8B | -4.37% | -28.48% | 25.91 | 3.42 | -3.19% | -17.38% |
ISRG | 88.0B | 6.2B | 9.55% | -17.45% | 66.52 | 14.14 | 8.97% | -22.43% |
EW | 49.6B | 5.4B | 1.40% | -30.34% | 32.6 | 9.22 | 2.86% | 1.25% |
ALGN | 24.1B | 3.7B | 0.76% | -29.47% | 66.64 | 6.45 | -5.51% | -53.17% |
HOLX | 19.9B | 4.5B | 1.08% | 5.00% | 20.11 | 4.46 | -18.71% | -42.28% |
MID-CAP | ||||||||
PEN | 10.6B | 847.1M | 6.58% | 27.77% | -5.3K | 12.46 | 13.32% | -137.89% |
NVST | 6.6B | 2.6B | 3.10% | -18.44% | 27.03 | 2.56 | 2.40% | -18.20% |
CNMD | 3.1B | 1.0B | 7.16% | -31.03% | -38.98 | 3 | 3.45% | -228.84% |
TMDX | 2.4B | 93.5M | -7.87% | 185.38% | -65.44 | 25.37 | 208.83% | 18.06% |
LIVN | 2.3B | 1.0B | -9.74% | -47.60% | -26.53 | 2.24 | -1.31% | 36.50% |
SMALL-CAP | ||||||||
ESTA | 1.7B | 161.7M | -5.36% | -0.91% | -22.01 | 10.24 | 27.64% | -82.82% |
AVNS | 1.3B | 820.0M | 2.39% | -14.54% | 26.48 | 1.63 | 10.13% | 701.59% |
BLFS | 887.4M | 154.8M | -10.66% | -9.26% | -8.53 | 5.73 | 60.29% | -2309.58% |
INGN | 278.7M | 377.2M | -22.46% | -62.75% | -3.33 | 0.74 | 5.37% | -1222.79% |
SDC | 46.6M | 470.7M | -35.97% | -85.77% | -0.54 | 0.1 | -26.17% | 15.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | -0.1% | 30,772 | 30,808 | 31,070 | 31,686 | 31,785 |
S&GA Expenses | 0.5% | 10,368 | 10,314 | 10,312 | 10,292 | 10,318 |
EBITDA | -2.0% | 8,714 | 8,891 | 9,012 | 8,777 | - |
EBITDA Margin | -1.9% | 0.28* | 0.29* | 0.29* | 0.28* | - |
Earnings Before Taxes | -3.8% | 5,416 | 5,630 | 5,728 | 5,517 | 5,481 |
EBT Margin | -3.7% | 0.18* | 0.18* | 0.18* | 0.17* | - |
Interest Expenses | 5.3% | 592 | 562 | 580 | 553 | 552 |
Net Income | -6.0% | 4,065 | 4,323 | 5,207 | 5,039 | 4,920 |
Net Income Margin | -5.9% | 0.13* | 0.14* | 0.17* | 0.16* | - |
Free Cahsflow | -13.6% | 4,166 | 4,822 | 5,721 | 5,978 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 1.0% | 94,134 | 93,241 | 89,914 | 90,981 | 91,804 |
Current Assets | -0.1% | 25,364 | 25,398 | 22,135 | 23,059 | 23,303 |
Cash Equivalents | -6.4% | 4,521 | 4,828 | 2,140 | 3,714 | 3,479 |
Inventory | 6.3% | 5,375 | 5,055 | 4,809 | 4,616 | 4,514 |
Net PPE | 2.6% | 5,437 | 5,298 | 5,281 | 5,413 | 5,251 |
Goodwill | 2.8% | 41,565 | 40,417 | 40,324 | 40,502 | 41,346 |
Liabilities | 3.2% | 42,516 | 41,184 | 37,071 | 38,260 | 39,091 |
Current Liabilities | -0.3% | 14,422 | 14,465 | 14,049 | 12,394 | 8,927 |
Long Term Debt | 7.0% | 22,210 | 20,753 | 17,481 | 20,372 | 24,290 |
Shareholder's Equity | -0.5% | 51,618 | 51,880 | 52,843 | 52,551 | 52,542 |
Retained Earnings | 1.1% | 30,117 | 29,799 | 30,276 | 30,250 | 29,607 |
Additional Paid-In Capital | 0.3% | 24,513 | 24,442 | 24,335 | 24,566 | 25,814 |
Accumulated Depreciation | 3.5% | 8,489 | 8,199 | 8,043 | 7,952 | 7,823 |
Shares Outstanding | 0.0% | 1,330 | 1,330 | 1,329 | 1,331 | 1,343 |
Minority Interest | 0% | 177 | 177 | 170 | 171 | 171 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -10.4% | 5,636 | 6,290 | 7,137 | 7,346 | 7,034 |
Share Based Compensation | 0.9% | 352 | 349 | 352 | 359 | 356 |
Cashflow From Investing | 5.2% | -2,747 | -2,897 | -2,460 | -1,659 | -11.00 |
Cashflow From Financing | -90.1% | -2,019 | -1,062 | -5,231 | -5,336 | -8,516 |
Dividend Payments | 1.6% | 3,554 | 3,497 | 3,440 | 3,383 | 3,321 |
Buy Backs | -14.1% | 1,887 | 2,196 | 2,469 | 2,544 | 1,616 |
46.5%
32.7%
0%
Y-axis is the maximum loss one would have experienced if Medtronic was unfortunately bought at previous high price.
7.6%
2.8%
1.7%
-3.2%
FIve years rolling returns for Medtronic.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-17 | American Portfolios Advisors | added | 32.5 | 512,240 | 3,178,580 | 0.14% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -4.21 | -192,074 | 2,503,930 | 0.07% |
2023-03-13 | Claro Advisors LLC | added | 36.89 | 101,369 | 650,369 | 0.21% |
2023-03-10 | MATHER GROUP, LLC. | reduced | -11.21 | -142,091 | 835,909 | 0.02% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 1.07 | -948,671 | 33,858,300 | 0.04% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -5.3 | -11,099,700 | 114,288,000 | 0.12% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -18.5 | -89,147 | 403,853 | 0.03% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 751,083 | 751,083 | 0.19% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -63.1 | -95,801,000 | 52,760,000 | 0.26% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -2.5 | -24,416 | 379,584 | 0.02% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 15, 2023 | blackrock inc. | 9.2% | 122,349,678 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.41% | 125,126,702 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 8.0% | 107,903,361 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 8.27% | 111,286,018 | SC 13G/A | |
Feb 03, 2021 | wellington management group llp | 2.87% | 38,648,749 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 7.96% | 107,107,760 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 8.55% | 114,617,479 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 8.2% | 109,561,921 | SC 13G/A | |
Jan 27, 2020 | wellington management group llp | 5.13% | 68,769,139 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 35.91 -55.42% | 41.64 -48.31% | 52.06 -35.37% | 70.57 -12.39% | 85.32 5.92% |
Current Inflation | 33.90 -57.91% | 38.84 -51.78% | 47.68 -40.81% | 63.17 -21.58% | 75.31 -6.51% |
Very High Inflation | 31.40 -61.02% | 35.42 -56.03% | 42.43 -47.32% | 54.54 -32.29% | 63.82 -20.77% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 30, 2023 | 8-K | Current Report | |
Mar 24, 2023 | 424B5 | Prospectus Filed | |
Mar 24, 2023 | FWP | Prospectus Filed | |
Mar 23, 2023 | 424B3 | Prospectus Filed | |
Mar 15, 2023 | 25-NSE | 25-NSE | |
Mar 10, 2023 | 25-NSE | 25-NSE | |
Mar 09, 2023 | 8-K | Current Report | |
Mar 07, 2023 | 8-K | Current Report | |
Mar 03, 2023 | S-3ASR | S-3ASR | |
Mar 01, 2023 | 10-Q | Quarterly Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-01 | Kirk Jennifer M | sold (taxes) | -57,637 | 85.77 | -672 | chief accounting officer |
2022-12-13 | Salmon Sean | acquired | 920,027 | 55.32 | 16,631 | evp & president cardiovascular |
2022-12-13 | Salmon Sean | sold | -1,338,740 | 80.4964 | -16,631 | evp & president cardiovascular |
2022-12-09 | Fong Ivan K | sold (taxes) | -409,140 | 78.59 | -5,206 | evp general counsel & secr |
2022-12-07 | WHITE ROBERT JOHN | sold (taxes) | -27,505 | 79.04 | -348 | evp & pres. medical surgical |
2022-12-07 | Wall Brett A. | sold (taxes) | -26,636 | 79.04 | -337 | evp & pres neuroscience |
2022-12-07 | Salmon Sean | sold (taxes) | -23,712 | 79.04 | -300 | evp & president cardiovascular |
2022-10-14 | TEN HOEDT ROB | sold | -196,015 | 81.537 | -2,404 | evp and pres. global regions |
2022-10-14 | TEN HOEDT ROB | acquired | 100,006 | 41.6 | 2,404 | evp and pres. global regions |
2022-08-01 | Smith Gregory L | acquired | - | - | 5,587 | evp global ops & supply chain |
Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Jan. 27, 2023 | Jan. 28, 2022 | Jan. 27, 2023 | Jan. 28, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 7,727,000,000 | $ 7,763,000,000 | $ 22,682,000,000 | $ 23,597,000,000 |
Costs and expenses: | ||||
Cost of products sold, excluding amortization of intangible assets | 2,689,000,000 | 2,459,000,000 | 7,740,000,000 | 7,554,000,000 |
Research and development expense | 688,000,000 | 668,000,000 | 2,055,000,000 | 2,094,000,000 |
Selling, general, and administrative expense | 2,615,000,000 | 2,561,000,000 | 7,799,000,000 | 7,723,000,000 |
Amortization of intangible assets | 431,000,000 | 432,000,000 | 1,275,000,000 | 1,298,000,000 |
Restructuring charges, net | 38,000,000 | 12,000,000 | 81,000,000 | 32,000,000 |
Certain litigation charges, net | 0 | 35,000,000 | 0 | 95,000,000 |
Other operating (income) expense, net | (125,000,000) | (63,000,000) | (187,000,000) | 719,000,000 |
Operating profit | 1,392,000,000 | 1,659,000,000 | 3,920,000,000 | 4,081,000,000 |
Other non-operating income, net | (149,000,000) | (67,000,000) | (342,000,000) | (244,000,000) |
Interest expense, net | 167,000,000 | 137,000,000 | 449,000,000 | 410,000,000 |
Income before income taxes | 1,375,000,000 | 1,589,000,000 | 3,813,000,000 | 3,915,000,000 |
Income tax provision | 146,000,000 | 106,000,000 | 1,218,000,000 | 346,000,000 |
Net income | 1,229,000,000 | 1,483,000,000 | 2,595,000,000 | 3,570,000,000 |
Net income attributable to noncontrolling interests | (6,000,000) | (4,000,000) | (17,000,000) | (16,000,000) |
Net income attributable to Medtronic | $ 1,222,000,000 | $ 1,480,000,000 | $ 2,579,000,000 | $ 3,554,000,000 |
Basic earnings per share (usd per share) | $ 0.92 | $ 1.10 | $ 1.94 | $ 2.64 |
Diluted earnings per share (usd per share) | $ 0.92 | $ 1.10 | $ 1.94 | $ 2.63 |
Basic weighted average shares outstanding (shares) | 1,330.2 | 1,343.7 | 1,329.6 | 1,344.4 |
Diluted weighted average shares outstanding (shares) | 1,332.0 | 1,350.3 | 1,332.8 | 1,353.9 |
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jan. 27, 2023 | Apr. 29, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,521 | $ 3,714 |
Investments | 6,616 | 6,859 |
Accounts receivable, less allowances and credit losses of $207 and $230, respectively | 5,887 | 5,551 |
Inventories, net | 5,375 | 4,616 |
Other current assets | 2,965 | 2,318 |
Total current assets | 25,364 | 23,059 |
Property, plant, and equipment | 13,926 | 13,365 |
Accumulated depreciation | (8,489) | (7,952) |
Property, plant, and equipment, net | 5,437 | 5,413 |
Goodwill | 41,565 | 40,502 |
Other intangible assets, net | 15,265 | 15,595 |
Tax assets | 3,361 | 3,403 |
Other assets | 3,142 | 3,008 |
Total assets | 94,134 | 90,981 |
Current liabilities: | ||
Current debt obligations | 5,918 | 3,742 |
Accounts payable | 2,209 | 2,276 |
Accrued compensation | 2,007 | 2,121 |
Accrued income taxes | 657 | 704 |
Other accrued expenses | 3,630 | 3,551 |
Total current liabilities | 14,422 | 12,394 |
Long-term debt | 22,210 | 20,372 |
Accrued compensation and retirement benefits | 1,103 | 1,113 |
Accrued income taxes | 2,305 | 2,087 |
Deferred tax liabilities | 747 | 884 |
Other liabilities | 1,730 | 1,410 |
Total liabilities | 42,516 | 38,260 |
Commitments and contingencies (Note 16) | ||
Shareholders’ equity: | ||
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,376,287 and 1,330,743,395 shares issued and outstanding, respectively | 0 | 0 |
Additional paid-in capital | 24,513 | 24,566 |
Retained earnings | 30,117 | 30,250 |
Accumulated other comprehensive loss | (3,189) | (2,265) |
Total shareholders’ equity | 51,441 | 52,551 |
Noncontrolling interests | 177 | 171 |
Total equity | 51,618 | 52,722 |
Total liabilities and equity | $ 94,134 | $ 90,981 |